Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06892639 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Evaluation of D-Fi for the Treatment of Wounds Due to DEB

StatusActive, Not Recruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Trial status: Recruiting to Active, Not Recruiting
    • Site details revised at 4 of 4 sites
    v8
  2. Study description expanded, about 28 words
    • Eligibility criteria expanded, about 2 words
    v7
  3. Study sites: 5 to 4v6
  4. Site details revised at 1 of 5 sitesv5
  5. Site details revised at 1 of 5 sitesv4
Show 2 earlier versionsHide 2 earlier versions
  1. Start date changed from estimate of Mar 2025 to Mar 27, 2025
    • Eligibility criteria revised
    • Site contacts updated at 5 of 5 sites
    v3
  2. Site details revised at 1 of 5 sitesv2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of this study is to determine whether administration of D-Fi in addition to standard of care improves wound healing as compared to standard of care alone (control) in children, adolescents, and adults with Dystrophic Epidermolysis Bullosa.
Trial Details
NCT Number NCT06892639
Lead Sponsor Castle Creek Biosciences, LLC.
Collaborators: Prosoft Clinical
Conditions
(from sponsor)		 Dystrophic Epidermolysis Bullosa
Related terms Epidermolysis Bullosa Dystrophica
Enrollment 32 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov